Altre lingue EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Azioni

PV3B

US30233G2093

Mercato chiuso - Deutsche Boerse AG Altri mercati azionari 15:29:01 31/05/2024			Variaz. 5gg	Var. 1 gen.
9,69 ^EUR	-3,34%		-4,06%	-54,29%

08/05	EYEPOINT PHARMACEUTICALS, INC. : Baird mantiene la raccomandazione Buy	ZM
08/05	EyePoint Pharmaceuticals, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

EYEPOINT PHARMACEUTICALS, INC. : Baird persiste à l'achat	08/05
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
EYEPOINT PHARMACEUTICALS, INC. : Opinion positive de Chardan Research	07/05
EYEPOINT PHARMACEUTICALS, INC. : Mizuho Securities toujours à l'achat	07/05
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint	06/05
Transcript : EyePoint Pharmaceuticals, Inc. - Special Call	06/05
EyePoint Pharmaceuticals, Inc. Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy	06/05
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02/04
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/03
Transcript : EyePoint Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024	07/03
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	04/03
EYEPOINT PHARMACEUTICALS, INC. : Mizuho Securities toujours à l'achat	15/02
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration	03/02
Eyepoint Pharmaceuticals Insider Sold Shares Worth $1,265,539, According to a Recent SEC Filing	30/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing	29/01
Eyepoint Pharmaceuticals Insider Sold Shares Worth $297,621, According to a Recent SEC Filing	26/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Azioni

PV3B

US30233G2093

Altre lingue

Filtri